Digital RESI Innovation Challenge

Vote for Me

Interested in Connecting? Please contact:
Tony Chen
CEO, Co-founder
Tony.chen@primevax.com

Message the company or request a 1:1 meeting here

PrimeVax is a clinical stage biotech and the world’s first company developing a cancer immunotherapy using dengue virus (DV). Our non-genetically modified DV strain is well-tolerated and includes 20+ years of human safety data and has the ability to address many cancer types. Our pipeline includes other DV and cell-based investigational therapies.

DV has novel MOAs: DV induces a systemic immune response, upregulates cancer killing cytokines, and DV supernatant proteins can directly kill tumors without the need for receptor cells.

Our pre-clinical models show a strong safety profile and promising early efficacy. We are IND-enabled, with clinical strategy blessed by the FDA. We are currently raising $3-8M to advance Phase 1 studies in PD-1 failed late stage Melanoma.